These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33733587)

  • 1. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
    Wang H; Nan S; Wang Y; Xu C
    J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.
    Shurin GV; Ferris RL; Tourkova IL; Perez L; Lokshin A; Balkir L; Collins B; Chatta GS; Shurin MR
    J Immunol; 2005 May; 174(9):5490-8. PubMed ID: 15843547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus.
    Jiang Y; Cao W; Wu K; Qin X; Wang X; Li Y; Yu B; Zhang Z; Wang X; Yan M; Xu Q; Zhang J; Chen W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):365. PubMed ID: 31429766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma.
    Tam K; Schoppy DW; Shin JH; Tay JK; Moreno-Nieves U; Mundy DC; Sunwoo JB
    Otolaryngol Head Neck Surg; 2018 Jul; 159(1):76-84. PubMed ID: 29436278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
    Crist M; Yaniv B; Palackdharry S; Lehn MA; Medvedovic M; Stone T; Gulati S; Karivedu V; Borchers M; Fuhrman B; Crago A; Curry J; Martinez-Outschoorn U; Takiar V; Wise-Draper TM
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma.
    Ma H; Chang H; Yang W; Lu Y; Hu J; Jin S
    Mol Cancer; 2020 Jan; 19(1):4. PubMed ID: 31907020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas.
    Elkashty OA; Abu Elghanam G; Su X; Liu Y; Chauvin PJ; Tran SD
    Carcinogenesis; 2020 Jun; 41(4):458-466. PubMed ID: 31742606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer.
    Jung EK; Chu TH; Vo MC; Nguyen HPQ; Lee DH; Lee JK; Lim SC; Jung SH; Yoon TM; Yoon MS; Cho D; Lee JJ; Cho HH
    Cytotherapy; 2022 Sep; 24(9):905-915. PubMed ID: 35778350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma.
    Mei Z; Zhang K; Lam AK; Huang J; Qiu F; Qiao B; Zhang Y
    Cancer Med; 2020 Jan; 9(2):640-652. PubMed ID: 31800160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma.
    Dong S; Zhao M; Zhu J; Li T; Yan M; Xing K; Liu P; Yu S; Ma J; He H
    Front Immunol; 2024; 15():1442673. PubMed ID: 39234249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
    Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
    Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance and biological functions of chemokine CXCL3 in head and neck squamous cell carcinoma.
    Guan J; Weng J; Ren Q; Zhang C; Hu L; Deng W; Lu S; Dong X; Li W; Li Y; Wang W
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34870709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
    Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
    Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CELSR3 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment.
    Wu Z; Zhu Z; Wu W; Hu S; Cao J; Huang X; Xie Q; Deng C
    Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3143-3156. PubMed ID: 38507078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of immunogenic cell death-related damage-related molecular patterns (DAMPs) to predict outcomes in patients with head and neck squamous cell carcinoma.
    Zhang J; Shi X; Wang M; Zhai R; Wang M; Gong Z; Ni Z; Xu T; Zhu W; Liu L
    J Cancer Res Clin Oncol; 2024 May; 150(5):240. PubMed ID: 38713284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma.
    Jung EK; Chu TH; Kim SA; Vo MC; Nguyen VT; Lee KH; Jung SH; Yoon M; Cho D; Lee JJ; Yoon TM
    Cytotherapy; 2024 Mar; 26(3):242-251. PubMed ID: 38142382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
    Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
    Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Glial cell derived neurotrophic factor in head and neck cancer.
    Cao H; He Q; Eyben RV; Bloomstein J; Nambiar DK; Viswanathan V; Aggarwal S; Kwok S; Liang R; Koong AJ; Lewis JS; Kong C; Xiao N; Le QT
    PLoS One; 2020; 15(2):e0229311. PubMed ID: 32084217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated fibroblast-derived exosomal microRNA-24-3p enhances colon cancer cell resistance to MTX by down-regulating CDX2/HEPH axis.
    Zhang HW; Shi Y; Liu JB; Wang HM; Wang PY; Wu ZJ; Li L; Gu LP; Cao PS; Wang GR; Ma YS; Fu D
    J Cell Mol Med; 2021 Apr; 25(8):3699-3713. PubMed ID: 33621425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.